Tom Jones’ Post

Thermo Fisher Scientific is on the brink of finalizing its $3.1 billion acquisition of Olink, a Swedish developer of protein analyzers and antibody tests, following clearance from the UK’s Competition and Markets Authority (CMA) on July 8. Key Points: 1. Regulatory Approval: - UK CMA: Cleared the acquisition after an investigation, deciding not to pursue a deeper probe. - Other Approvals: Received green lights from competition watchdogs in Iceland and Germany. 2. Market Impact: - Germany’s Bundeskartellamt: Assured that the merger will not significantly impact market competition or stifle research in the proteomics field. - U.K. CMA: Will publish additional details on its decision later, with no caveats included. 3. Deal Details: - Initial Announcement: Thermo Fisher announced the acquisition last October, agreeing to pay $26 per Nasdaq share of Olink, a 74% premium over the stock price at the time. - Olink’s Offerings: High-throughput protein analysis assays compatible with qPCR instruments and next-generation sequencers. International operations are based in Boston, Tokyo, and Shanghai. 4. Next Steps: - Tender Offer Deadline: Thermo Fisher’s tender offer for Olink’s outstanding shares is set to expire at 5:00 p.m. ET on July 9, 2024. - Deal Closure: The companies aim to close the deal by mid-July. Impact: This acquisition is set to enhance Thermo Fisher’s capabilities in proteomics, furthering advancements in life science research and precision medicine. Stay updated on key regulatory changes by following Global Regulatory Insights! #GRI #RegulatoryUpdates #Compliance #LegalIntelligence

Unlock the secrets to seamless small molecule contract development and manufacturing. Join our virtual symposium to learn from industry experts strategies to navigate the complexities of your small molecule drug development journey. From traditional APIs, to HPAPIs, to Next-Generation Conjugates and exciting new areas like Targeted Protein Degradation, our experts will share insights and case studies on strategic approaches to phase appropriate quality, first time right tech transfer, and much more: http://ms.spr.ly/6040i4HXw

Unlock the secrets of small molecule development and manufacturing. On February 22, join industry experts to learn how to solve your synthesis challenges and accelerate your small molecule drug program. Get insights on how to navigate the intricacies of developing, synthesizing, and sourcing across a wide range of segments such as HPAPIs, APIs, Next-Generation Conjugates, Linker-Payloads, PEGs, and Targeted Protein Degradation. Register now!

Unlock the secrets to seamless small molecule contract development and manufacturing. Join our virtual symposium to learn from industry experts strategies to navigate the complexities of your small molecule drug development journey. From traditional APIs, to HPAPIs, to Next-Generation Conjugates and exciting new areas like Targeted Protein Degradation, our experts will share insights and case studies on strategic approaches to phase appropriate quality, first time right tech transfer, and much more: http://ms.spr.ly/6049i4HXZ

Repligen Submits Bid for Reagent Vendor Maravai, Sources Say Repligen has approached Maravai LifeSciences Holdings, a vaccine capping reagent vendor that has a market value of about $2.5 billion, with an acquisition offer, according to people familiar with the matter. There is no certainty that Maravai will agree to a deal with Repligen, the sources said. Repligen is also deliberating whether it should divest some of Maravai's divisions if it succeeds in acquiring the company, the sources added. It has held talks with private equity firms, including EQT AB, about selling Maravai's nucleic acid production unit to them, according to the sources. The sources requested anonymity because the matter is confidential. Maravai has previously attracted acquisition interest from other suitors. In 2022, Maravai rebuffed a $42 per share all-cash offer from laboratory supplies vendor Sartorius AG, Reuters reported at the time. https://lnkd.in/gPMUWZ3E #aspenalert #biotech #bioprocess

Unlock the secrets of small molecule development and manufacturing. On February 22, join industry experts to learn how to solve your synthesis challenges and accelerate your small molecule drug program. Get insights on how to navigate the intricacies of developing, synthesizing, and sourcing across a wide range of segments such as HPAPIs, APIs, Next-Generation Conjugates, Linker-Payloads, PEGs, and Targeted Protein Degradation. Register now!

Unlock the secrets of small molecule development and manufacturing. On February 22, join industry experts to learn how to solve your synthesis challenges and accelerate your small molecule drug program. Get insights on how to navigate the intricacies of developing, synthesizing, and sourcing across a wide range of segments such as HPAPIs, APIs, Next-Generation Conjugates, Linker-Payloads, PEGs, and Targeted Protein Degradation. Register now!

Unlock the secrets of small molecule development and manufacturing. On February 22, join industry experts to learn how to solve your synthesis challenges and accelerate your small molecule drug program. Get insights on how to navigate the intricacies of developing, synthesizing, and sourcing across a wide range of segments such as HPAPIs, APIs, Next-Generation Conjugates, Linker-Payloads, PEGs, and Targeted Protein Degradation. Register now!

Unlock the secrets of small molecule development and manufacturing. On February 22, join industry experts to learn how to solve your synthesis challenges and accelerate your small molecule drug program. Get insights on how to navigate the intricacies of developing, synthesizing, and sourcing across a wide range of segments such as HPAPIs, APIs, Next-Generation Conjugates, Linker-Payloads, PEGs, and Targeted Protein Degradation. Register now!

Unlock the secrets of small molecule development and manufacturing. On February 22, join industry experts to learn how to solve your synthesis challenges and accelerate your small molecule drug program. Get insights on how to navigate the intricacies of developing, synthesizing, and sourcing across a wide range of segments such as HPAPIs, APIs, Next-Generation Conjugates, Linker-Payloads, PEGs, and Targeted Protein Degradation. Register now!